Tests metformin in older adults with multiple sclerosis
Tests metformin against placebo in older adults with multiple sclerosis.
Plain-language title generated from the registry record
Registry title: Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)
Key facts
- Where
- Buffalo, United StatesSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 55 and 75 years old?
Source: NCT06463743, who can take part
Where in United States
- UBMD NeurolgyBuffalo, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- State University of New York at Buffalo
- Trial code
- NCT06463743
- Record updated
- 6 November 2026
- Original description
The goal of the study is to learn about treating older people with multiple sclerosis (MS) with metformin. Metformin may be used as a single therapy or as an add-on therapy. The investigators want to learn:Read full original descriptionShow less
Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS): Randomized, Placebo-controlled Pilot Study.
The goal of the study is to learn about treating older people with multiple sclerosis (MS) with metformin. Metformin may be used as a single therapy or as an add-on therapy. The investigators want to learn:
* The safety and tolerability of metformin extended release (1500 mg/day) as a single therapy or as an add-on therapy in older people with MS compared to placebo * How well metformin protects the nervous system against injury compared with placebo measured by brain MRI over a 9 month treatment period * The effect of metformin to protect brain tissue from age and MS related injury when compared to the placebo group over a 9 month treatment period
Inclusion: age between 55 and 75 years old; having a diagnosis of MS based on the latest McDonald criteria; non-active disease course (no relapses and no MRI activity) in the last 2 years as determined by the MS provider and based on the 2020 revised clinical course criteria; EDSS score <7.0.
Exclusion: diabetes or uncontrolled cardiovascular disease; inability to undergo MRI scans; inability to participate in the study during the study period; unable to consent.